Fifteen percent of EOC tumors carry mutations or deletions of BRCA1 or BRCA2 [3], a defect in homologous recombination (HR) that renders these tumor cells vulnerable to synthetic lethality induced by inhibitors of poly (ADP-ribose) polymerase (PARP). The gene discussed is BRCA2; the disease is neoplasm.